阿巴西普注射液是皮下注射还是静脉注射

Bristol-Myers Squibb (BMS) said not long ago that the U.S. FDA has approved the company's drug for the treatment of adult patients with active psoriatic arthritis (PsA), a chronic inflammatory disease that affects the patient's skin and musculoskeletal system.

The marketed dosage forms of abatacept injection will include intravenous injection and subcutaneous injection preparations. The drug cannot be used simultaneously with TNF antagonists, and it is not recommended to be used in conjunction with other rheumatoid arthritis biologics such as anakinra injection. The approval of abatacept injection for the treatment of active psoriatic arthritis is the third autoimmune indication for which the drug has been approved.

Brian J. Gavin, vice president of BMS and head of ORENCIA development, said: "The approval of ORENCIA confirms the drug's efficacy in the treatment of active psoriatic arthritis in adults who are in urgent need of new treatments. Helping people better understand autoimmune diseases is a key focus of the company's immune science research, and we are very proud to bring the selective T cell costimulation modulator abatacept injection to the market as a new option for PsA treatment."

The co-stimulation blocking mechanism of abatacept injection can inhibit T cell activation and subsequent inflammation-related cascade reactions. T cell activation is involved in the major pathogenesis of PsA.

Psoriatic arthritis can cause joint pain, stiffness, and reduced range of motion in patients, and can potentially affect patients' daily activities, such as putting on clothes and tying shoes. In people with PsA, their immune systems attack normal joints and skin tissue.

Randy Beranek, President and CEO of the National Psoriasis Foundation, said: "Psoriatic arthritis has always placed a great burden on patients' families. We welcome the introduction of new active psoriatic arthritis treatments to the market. We also firmly believe that with the progress of drug development, patient education and the strengthening of supportive services, they will play a vital role in improving the quality of life of patients."

The approval of abatacept injection is based on the results of two randomized, double-blind, placebo-controlled clinical studies, which showed that it improved or reduced disease activity in patients who were not treated with TNF antagonists and those who had been treated with high mobility, high joint swelling, and a disease duration of more than 7 years.

Recommended related hot articles: /newsDetail/85481.html